Pulido-Díaz N, Angulo-Álvarez DM, López-Ibarra M

Language: Spanish
References: 11
Page: 59-62
PDF size: 39.55 Kb.

ABSTRACT

Toxic epidermal necrolysis and Stevens Johnson syndrome are severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes. We report a case of 43 year old female with 75 % body surface area affected, treated with intravenous immunoglobulin who presented favorable outcomes.

REFERENCES

1. Wanat KA, Anadkat MJ, Klekotka PA. Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole. J Am Acad Dermatol 2009;60(4):589-594.

2. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139(1):26-32.

3. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129(1):92-96.

4. Ringheanu M. Toxic epidermal necrolysis in children. An update. Clin Pediatr 2000;39(12):687.

5. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007;56(2):181-200.

6. Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol 2008;122(5):992-1000.

7. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139(1):33-36. Disponible en http://archderm.amaassn. org/cgi/content/full/139/1/33

8. Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol 2007;87(3):206-218. Disponible en http://www.medicaljournals.se/acta/content/ ?doi=10.2340/00015555-0249

9. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139(1):26-32.

10. Trent JT, Fangchao M, Kerdel F, Fie S, French LE, Romanelli P, Kirsner RS. Dose of intravenous immunoglobulin and patient survival in SJS and toxic epidermal necrolysis. Expert Rev Dermatol 2007;2(3):299-303.

11. Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol 2006;97(3):272- 280.